The GLP-1 patent race is more complex than you think
Everyone is talking about semaglutide and tirzepatide. The blockbuster revenues, the obesity boom , the reshaping of pharma valuations. But while the commercial story dominates headlines, a quieter and arguably more consequential race is playing out in patent offices across the globe. The question isn't whether GLP-1 generics are coming. It's when, where, and through how many layers of IP they'll have to fight. Here's what most market commentary misses: GLP-1 drugs don't sit behind a single patent wall. They carry layered protection including compound patents, formulation patents, delivery device patents, and method-of-use claims, each expiring independently, across different jurisdictions , on different timelines. Clearing the diabetes IP doesn't automatically open the door to the obesity indication . That's a separate and newer thicket, with filings that extend exclusivity well ...